Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-08 pm EST
85.67 USD   -0.44%
02/08Mexicans denounce US firm over high prices of vital medications
AQ
02/07UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating
MT
02/06Gilead Sciences, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : Gilead Sciences, Inc. Presents at NASDAQ 47th Investor Conference, Dec-07-2022 01:00 PM

12/07/2022 | 08:00am EST
All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead...


ę S&P Capital IQ 2022
All news about GILEAD SCIENCES, INC.
02/08Mexicans denounce US firm over high prices of vital medications
AQ
02/07UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating
MT
02/06Gilead Sciences, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F..
AQ
02/06Drug companies face huge drop in sales in 2023
RE
02/06U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
AQ
02/06Drug companies face COVID cliff in 2023 as sales set to plummet
RE
02/06Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead..
CI
02/03Ford, Starbucks fall; Clorox, Gilead Sciences rise
AQ
02/03Sector Update: Health Care Stocks Unable to Establish Direction
MT
02/03Sector Update: Health Care Stocks Flirting with Small Gains
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 26 518 M - -
Net income 2022 4 375 M - -
Net Debt 2022 16 339 M - -
P/E ratio 2022 24,7x
Yield 2022 3,42%
Capitalization 107 B 107 B -
EV / Sales 2022 4,64x
EV / Sales 2023 4,58x
Nbr of Employees 14 400
Free-Float 99,0%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 85,67 $
Average target price 90,13 $
Spread / Average Target 5,20%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-0.21%106 830
JOHNSON & JOHNSON-7.38%427 207
ELI LILLY AND COMPANY-7.15%322 756
NOVO NORDISK A/S3.00%313 215
MERCK & CO., INC.-3.88%267 941
ABBVIE INC.-10.52%256 590